Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 6/20 | 0.55 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.55 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.48 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7717119 | 0.90 | CYSLTR1 (0.49) | CYSLTR1CYSLTR2GPBAR1PDE10AALOX5 | |
| SCHEMBL7714623 | 0.82 | CYSLTR1 (0.56) | CYSLTR1CYSLTR2GPBAR1PDE10AALOX5AP | |
| SCHEMBL7717028 | 0.82 | CYSLTR1 (0.56) | CYSLTR1CYSLTR2GPBAR1PDE10AALOX5AP | |
| SCHEMBL7458688 | 0.81 | CYSLTR1 (0.67) | CYSLTR1GPBAR1ALOX5 | |
| SCHEMBL7455455 | 0.81 | CYSLTR1 (0.67) | CYSLTR1GPBAR1ALOX5 | |
| SCHEMBL10846145 | 0.78 | PDE10A (0.68) | CYSLTR1CYSLTR2GPBAR1PDE10ACYP1A2 | |
| SCHEMBL9844652 | 0.78 | CYSLTR1 (0.69) | CYSLTR1CYSLTR2GPBAR1PDE10A | |
| SCHEMBL14021613 | 0.77 | CYSLTR1 (0.63) | CYSLTR1CYSLTR2GPBAR1PDE10ACYP1A2 | |
| SCHEMBL8636013 | 0.77 | PDE10A (0.63) | CYSLTR1CYSLTR2GPBAR1PDE10ACYP1A2 | |
| SCHEMBL7716747 | 0.76 | CYSLTR1 (0.67) | CYSLTR1CYSLTR2GPBAR1ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |